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Introduction
Currently nearly 50% of all anti-cancer therapies are platinum (Pt)-based [1, 2] . Surprisingly only three Pt-based drugs have been approved for worldwide clinical use, namely cisplatin, carboplatin and oxaliplatin ( Fig. 1 ) while three others; nedaplatin, heptaplatin and lobaplatin, have been approved only in Japan, South Korea and China, respectively [1, 3] . The cytotoxicity of Pt drugs is attributed to their ability to bind DNA and thereby induce DNA damage and ultimately apoptosis [3, 4] . The application and efficacy of Pt drugs is limited by drawbacks though such as (i) intrinsic or acquired resistance and (ii) toxicity [3, 4] . Therefore, strong incentives exist for the development of innovative strategies that generate novel Pt compounds which have different modes of action to those of clinically used Pt drugs. It is conceivable that such novel Pt compounds would potentially target a broader spectrum of human cancers, and in particular cancers where resistance has already emerged to Pt drugs.
Farrell and co-workers initiated a resurgence of interest in the development of trans Pt compounds as potential anti-cancer agents [5, 6] . Although transplatin for example (Fig. 2) is chemotherapeutically inactive, they demonstrated that substitution of the NH 3 carrier ligands of transplatin by N-donor heterocycles such as pyridine (py) or thiazole activated a trans geometry. These so called "trans-platinum planar amine" (TPA) complexes (Fig. 2) have comparable cytotoxicities to those seen with both their cis-isomers and that of cisplatin, while retaining activity against tumour cell lines resistant to cisplatin [5] [6] [7] [8] . Trans platinum compounds possessing alternative carrier ligands to the N-donor heterocycles such as iminoethers, aliphatic amines and aliphatic heterocyclic amines (Fig. 2) were also investigated and shown to exhibit good activity [9, 10] .
More recently, Farrell and co-workers improved the profile of their TPA complexes by replacing the chlorido leaving groups with carboxylato ligands [11, 12] . These trans-[Pt(O 2 CR) 2 (L)(L′)] (where L and L′ are N-donor heterocycles or ammine ligands) or Pt compounds with N 2 O 2 donor sets have similar cytotoxicities to their N 2 Cl 2 analogues but offer distinct advantages of being more water soluble, stable to hydrolysis and displaying greater accumulation in cisplatinresistant tumour cells [11] [12] [13] [14] .
We are interested in combining platinum compounds with molecularly targeted anti-cancer drugs, particularly histone deacetylase (HDAC) inhibitors (HDACIs) [15, 16] . Histones are the main protein component of chromatin, around which DNA coils. HDACs are a class of zinc metalloenzymes that deacetylate core histone lysine residues, which results in a condensed chromatin structure and ultimately transcriptional repression [17] . Inhibition of HDAC function therefore dramatically affects chromatin structure and thus function.
More recently HDACIs have been shown to target non histone proteins such as proteins involved in cellular proliferation, migration, death, DNA repair, angiogenesis, inflammation and the immune response [18] . A range of structurally diverse HDACIs have been shown to be effective anti-cancer agents via multiple mechanisms, including inducing cell-cycle arrest, intrinsic and extrinsic apoptotic mechanisms, mitotic cell death, autophagic cell death, generation of reactive oxygen species, inhibiting angiogenesis, and improving NK cell-mediated tumour immunity [17, 18] . Several of these inhibitors are now undergoing clinical trials [19] . Suberoylanilide hydroxamic acid (SAHA, vorinostat), (Fig. 3) was the first FDA-approved pan-HDACI to enter the clinic as a treatment for cutaneous T-cell lymphoma [20] . SAHA is also well tolerated in patients, particularly at doses which exhibit a potent anti-cancer effect [21, 22] .
We recently devised a strategy to derivatise SAHA in such a way so as to facilitate its binding to Pt, while not compromising its HDAC inhibitory activity. In doing so we developed a novel anti-cancer bifunctional Pt drug candidate with dual DNA binding and HDAC inhibitory activity, cis-[Pt(NH 3 ) 2 (malSAHA −2H )] (Fig. 3) [15] .
Valproic acid (VPA, 2-propylpentanoic acid), (Fig. 3) , a clinically used drug for the treatment of epilepsy, has also been shown to possess HDAC inhibitory activity, along with anti-metastatic and anticancer activities [23] . Consequently, it is currently undergoing clinical trials as an anti-cancer agent either as a single agent, or as part of different combination regimens [24] . In addition, VPA has been shown to exhibit synergistic activity with cisplatin [25] and resensitise cells that have acquired resistance to cisplatin [26] .
Given our interest in Pt complexes [15, [27] [28] [29] [30] and HDAC inhibitors [15, 16, 31] , and the emergence of the TPA complexes with the N 2 O 2 donor set [8] , we sought to develop novel TPA complexes of VPA. We speculated that VPA would enhance the activity of TPA complexes as anti-cancer agents and in doing so target a broader spectrum of human cancers than clinically used Pt drugs. We envisaged that our TPA valproato complexes would hydrolyse in much the same way as carboplatin [32, 33] in cells but releasing valproato ligands free to inhibit HDACs and the resulting cytotoxic TPA moiety free to bind DNA nucleobases. Herein we describe the synthesis, characterisation, in vitro cytotoxic activity against cisplatin sensitive and resistant ovarian cancer cell lines (A2780 and A2780 cisR) and mutagenicity of novel TPA valproato complexes.
Experimental

Materials and instrumentation
Sodium valproate, metal salts, solvents and deuterated solvents were all purchased from Sigma Aldrich and used without further purification. Trans-[PtCl 2 (NH 3 )(py)] and trans-[PtCl 2 (py) 2 ] (where py is pyridine) were prepared by the methods of Ma [11] and Kaufman [34] , respectively. IR spectra were recorded as KBr discs (4000-400 cm
) on a Mattson Genesis II CSI FTIR spectrometer and the spectra analysed using WinFirst software. 1 H NMR spectra were recorded on a Bruker Avance 400 NMR spectrometer and the spectra analysed using TopSpin 1 software. The residual undeuterated DMSO signal at 2.505 ppm was used as an internal reference. Liquid chromatography-mass spectrometry experiments were performed on a Quattro Micro quadrupole electrospray mass spectrometer (Micromass, Waters Corp., USA): 10 μL of the samples were injected in 300 μL of acetonitrile:water (60:40, v/v). The mass spectrometry data were acquired both in positive and negative ion modes. Elemental analysis (C, H, and N) were performed by the RCSI Analytical Service, Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Ireland.
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Carboplatin Oxaliplatin Fig. 1 . Structures of cisplatin, carboplatin and oxaliplatin. Fig. 2 . Structures of transplatin and cytotoxic trans platinum compounds where py is pyridine, tz is thiazole and ipa is isopropylamine. 
Crystallographic measurements on trans-[Pt(VPA -1H ) 2 (NH 3 )(py)]
Single crystals of trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] suitable for an X-ray study were obtained by slow evaporation from the mother liquor and as thin plates with relatively weak reflection ability. Crystal data (Table 1) was collected on SMART APEX2 CCD diffractometer at 100 K using monochromated Mo-K α radiation, (λ = 0.71073 Å). An analysis of the measured intensities was carried out with the SAINT and SADABS programmes included in the APEX2 programme package [35] , taking into account an absorption correction by the semi-empirical method. The structures were solved by the direct methods and refined by the fullmatrix least-squares procedure against F 2 in anisotropic approximation.
Ammonium hydrogen atoms were located in the difference Fourier maps and were then shifted at the standard X-ray values for N-H bonds (0.9 Å) and included in the refinement using riding approximation (U iso (H) = 1.2U eq (N)). All the other hydrogen atoms were placed in geometrically calculated positions and refined within riding model (U iso (H) = nU eq (C), where n = 1.5 for methyl hydrogen atoms and n = 1.2 for all the other hydrogens). The refinement was carried out with the SHELXTL programme [36] .
Mutagenicity
The possible genotoxicity of test agents was investigated using the Standard Ames bacterial mutation assay described by Maron and Ames [37] . The primary tester strains used were Salmonella typhimurium strains TA98 and TA100 (Trinova, Germany), which detect mutation by frame-shift and base-pair substitution, respectively. Both strains carry the ampicillin resistance plasmid pKM101. Tester strains were cultured in Oxoid nutrient broth No. 2 to a cell density of 1 × 10 9 cells/mL (OD of 0.60 at 605 nm) and maintained on master plates for routine inoculation. Both tester strains were then grown on minimal glucose plates, supplemented with 0.5 mM histidine/biotin and ampicillin.
To carry out the Ames test, top agar [0.3% (w/v) agar and 0.5% (w/v) NaCl] was supplemented with 10 mL of 0.5 mM histidine/biotin per 100 mL of agar, immediately prior to use. A 2 mL aliquot of top agar was distributed into a sterile universal. A mammalian enzyme activation system was also included, which consisted of the S9 liver fraction of a male Sprague-Dawley rat, induced with aroclor 1254. A 500 μl aliquot of S9 mixture (10%, v/v), 100 μl of test agent at the appropriate concentration dissolved in 0.1 M PBS, pH 7.4, and 100 μl of tester strains were added to 2 mL aliquots of molten top agar, mixed and quickly poured over the surface of minimal glucose plates lacking histidine/ biotin. All plates were then protected from light, allowed to solidify, inverted and then incubated at 37°C for 72 h. Following incubation, the number of revertant colonies was determined per plate. Each test concentration was analysed in triplicate, in both the presence and absence of the S9 enzyme activation system. Negative control plates used consisted of tester strain and S9 mix alone, while the solventtreated control consisted of tester strain, S9 mixture and solvent vehicle (no test agent). This approach allowed identification and quantification of spontaneous bacterial revertants. Positive controls included the known mutagens, 4-nitroquinoline-N-oxide (NQNO) for TA98 (1-1000 ng/plate) and sodium azide (0.5-10 μg/plate) for TA100. The metabolising activity of the rat liver S9 was tested in both strains using 2-aminoanthracene, as this mutagen required metabolic activation in order to induce mutations.
In vitro cytotoxicity
The in vitro anti-cancer chemotherapeutic potential of our test agents was determined using two human-derived malignant ovarian model cell lines; A2780 and A2780 cisR. Both cell lines were purchased from the European Collection of Cell Cultures and maintained in RPMI-1640 media with Earle's balanced salt solution (EBSS) containing 1.5 g/L sodium bicarbonate, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, along with 10% (v/v) foetal bovine serum (FBS). All cell culture reagents were purchased from Sigma-Aldrich Ireland, Ltd, unless otherwise stated.
The cisplatin-resistant human ovarian cell line, namely A780 cisR, was previously developed by chronic exposure of the parent cisplatin sensitive A2780 cell line to increasing concentrations of cisplatin. A2780 cisR cells are known to be cross-resistant to melphalan, adriamycin and irradiation. Resistance was maintained by, every third passage, culturing these cells in 1 μM cisplatin, and cells were maintained as above. Both model cell lines were incubated at 37°C in a humidified atmosphere, containing 95% air with 5% CO 2 .
Each of the two cell lines (100 μl) were seeded at a density of 5 × 10 4 cells/mL into sterile 96 wells of flat-bottomed plates and grown in 5% CO 2 at 37°C. Test compounds were dissolved in dimethylformamide (DMF) and diluted with complete culture media. The maximum percentage of DMF present in all wells was 0.5% (v/v). Each drug solution (100 μl) was added to replicate wells in the concentration range of 1-100 μM, and incubated for 72 h. A miniaturised viability assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was carried out according to the method described previously [38] . The IC 50 value for each drug was calculated and this is defined as the drug concentration causing a 50% reduction in cellular viability. Each assay was carried out using five replicates and repeated on three separate occasions. Viability was calculated as a percentage of solventtreated control cells, and expressed as a % of control. The significance of any reduction in cellular viability was determined using one-way ANOVA (analysis of variance). A probability of 0.05 or less was deemed statistically significant.
Results and discussion
Syntheses of platinum valproic acid complexes
The ⁎ Atoms denoted with letters A and B are generated by symmetry codes −x, y, −z + 1/2 and −x + 1, y, −z + 1/2, correspondingly. C11 and C10, Fig. 4) are found at 8.52, 8 .03 and 7.54 ppm respectively but integrate for 5 protons in total. In trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] the ammine proton signal is found at 4.73 ppm and integrates for three protons. The methine (C2), methylene (C3 and C4) and methyl (C5) proton signals of the bound VPA −1H ligands, Fig. 4 , are found at 2.08, 1.33, 1.11 and 0.79 ppm and also integrate in total for 30 protons.
In the 13 C NMR spectrum of both symmetrical complexes the carbonyl carbon signal (C1) is found at ca. 183 ppm and the three pyridine carbon signals (C9, C11 and C10) are found at ca. 150, 138 and 125 ppm respectively, Fig. 4 . The methine (C2), methylene (C3 and C4) and methyl (C5) carbon signals of the bound VPA −1H ligands, Fig. 4 , are found at ca. 46, 35, 20 and 13 ppm respectively for both complexes.
ESI-MS in the positive mode was used to assist in identifying the platinum complexes; mass peaks at 640.23 and 578.19 amu were observed for trans-[Pt(VPA −1H ) 2 (py) 2 ] and trans-[Pt(VPA −1H ) 2 (NH 3 ) (py)] respectively. All of the spectra display the correct isotopic patterns.
An X-ray crystal structure was solved for trans-[Pt(VPA −1H ) 2 (NH 3 ) (py)].
Crystal structure of trans-[Pt(VPA −1H ) 2 (NH 3 )(py)]
The atomic numbering scheme and atom connectivity for trans-[Pt (VPA −1H ) 2 (NH 3 )(py)] is shown in Fig. 4 and a selection of bond lengths and angles are reported in Table 2 .
An asymmetric unit cell of trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] contains two halves of Pt-complexes (A and A′) which are both located on the two-fold symmetry axes. The ammine protons are disordered over two symmetrical positions with equal occupancies. A general view of these molecules is shown in Fig. 4 . In both complexes, the platinum atom adopts square planar geometry. All the N-Pt-N, N-Pt-O and O-Pt-O angles are nearly 90°and 180°, correspondingly (see Table 1 ). The valproic carboxylato groups in both molecules are nearly perpendicular to the alkyl chains of the valproato ligands. The disparity between the two independent Pt complexes is in the orientation of the pyridine ligand. There is a difference in rotation about Pt1-N1(Pt1′-N1′) bond; in molecule A the torsion angle for O1-Pt1-N1-C9 is −59.4(3)°where as in molecule A′ it is −23.0(3)°. This results in a slightly shortened C9′-H9′ A…O1′ contact (C…O is 2.960(7) Å, H…O is 2.42 Å, bCHO is 116°) in A′. In molecule A, this distance corresponds to a normal nonbonded contact (H9…O1 is 3.02 Å, no H-bond is formed). Therefore the orientation of the pyridine ring is predominantly defined by the effect of the crystal packing rather than by the intramolecular C-H…O interaction.
In the crystal, the Pt molecules are connected to each other by a H-bond network. The ammine protons are H-bonded to the carboxylato O2(O2′) atoms (Table 3 ). This leads to the formation of H-bond chains in the direction of the a axis. Each chain is built up of alternate A and A′ molecules. In the ab plane, these chains are interpenetrated by pyridine moieties. Two adjacent pyridine rings from different chains are nearly perpendicular to each other; the closest intermolecular distance is observed between C11′…H9A atoms and is equal to 3.00 Å. This does not imply any strong interchain interactions but such packing is responsible for the different orientation of the pyridine rings in A and A′.
Mutagenicity
The mutagenicity of our test agents was determined using the Ames test and the data is presented in Figs. 5 and 6 . For a compound to be considered as a possible mutagen, a fold-related increase in revertant colonies must be observed with increasing concentration. Data presented shows that trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] increased the number of revertant colonies in both TA98 and 100 cells both with and without S9. By contrast, trans-[PtCl 2 (NH 3 )(py)] was only found to be mutagenic in TA100 cells, and in the presence of the S9 fraction. Therefore, trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] and trans-[PtCl 2 (NH 3 )(py)] may be considered possible mutagens, a trend similar to that observed for cisplatin [40, 41] .
In vitro cytotoxicity
The in vitro anti-cancer chemotherapeutic potential of a series of TPA dichlorido compounds and their corresponding TPA valproato analogues were determined using two human-derived ovarian cancer cell lines; parental cell line A2780 and cisplatin resistant variant A2780 cisR. Dose-response curves were plotted (data not shown) and used to calculate IC 50 values (Table 4) . Sodium valproate and transplatin were shown to be inactive in both cell lines. Additionally, the TPA compounds; trans-[PtCl 2 (py) 2 ] and trans-[PtCl 2 (NH 3 )(py)] exhibited little or no cytotoxicity at the maximum concentration used (100 μM). Previously it has been shown that when the NH 3 group of transplatin is substituted with N-donor heterocycle ligands, such as pyridine, a cytotoxicity profile equivalent to that of cisplatin was observed [6] . (4-pic) ], (4-pic = 4 picolinic acid), which displayed the fastest hydrolysis and was the most water soluble of the TPA complexes studied had an IC 50 of 6 μM against the A2780 cell line for example [13] .
Conclusion
The first examples of Pt complexes of the well known anti-epilepsy drug and HDAC inhibitor, valproic acid, trans-[Pt(VPA −1H ) 2 T ra n s p la ti n tr a n s -[ P tC l2 (p y )2 ] tr a n s -[ P t( V P A )2 (p y )2 ] tr a n s -[ P tC l2 (N H 3 )( p y )] tr a n s -[ P t( V P Fold increase in revertant colonies relative to control Fig. 6 . Standard Ames tests were used to determine the mutagenic potential of all test compounds using TA100 Salmonella typimurium tester strain, both in the presence and absence of a S9 fraction isolated from rat hepatocytes. Results presented for (A) TA100 (−)S9 and (B) TA100 (+)S9, for test agents at a concentration range of 10-10,000 ng/plate. Bars indicate ± SEM, n = 3.
monodentate manner. The X-ray crystal structure of the novel complex trans-[Pt(VPA −1H ) 2 (NH 3 )(py)] is also described. Replacement of the dichlorido ligands in TPA complexes significantly enhanced cytotoxicity against A2780 (parental) and A2780 cisR (cisplatin resistant) ovarian cancer cells. It is envisaged that development of TPA carboxylato complexes, where the carboxylic acid ligand is a more potent HDACI than valproic acid and one which would contribute positively to the hydrolysis and solubility profile of corresponding Pt complexes, may serve to enhance the cytotoxic potential of TPA complexes. 
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